Skip to main content

KPMG Deal Capsule Life Sciences November 2021

Page 1

Deal Capsule Transactions in Life Sciences November 2021

Life Sciences M&A activity continues its steady trend exceeding in Q3 2021 already the previous full year levels. Biotech and medical devices subsectors show the highest activity. Slightly declining valuations have fueled M&A activity yet growing investor skepticism and macro economic outlooks might change the confidence level going forward.

CHRISTIAN KLINGBEIL | PARTNER, KPMG IN GERMANY

HIGHLIGHTS — Continuous momentum in biotech and medical devices & diagnostics subsectors drove life sciences M&A activity in Q1-Q3 2021. — Focus of M&A activities was primarily on nutrition and healthcare, digitalization, robotic surgeries and novel therapeutics.

Trends in Life Sciences M&A 4.000

597 467

3.000 2.000 1.000

Y-o-Y

2,449

296

Volume

Value

+34%

+94% 326

285

265

222

2,530

2,611

2,832

2,768

2016

2017

2018

2019

168 3,161

2,367

3,166

0 2015

Number of Announced Deals

2020 Q1-Q3 2020 Deal Value in US$ bn.

Q1-Q3 2021

Subsector public EBITDA multiples(a) Pharmaceuticals

— Valuations declined slightly in Q3 2021 following growing investor skepticism partly in anticipation of rising interest rates. Time will tell whether this is only a temporary effect or a trend reversal.

Biotech 28.7x

14.7x

14.1x

Q2 2021

Q3 2021

Q2 2021

Medical devices & diagnostics 24.8x

Q3 2021

19.4x

Q2 2021

17.9x

Q3 2021

Deal Thermometer Q1-Q3 2021 — KPMG’s Deal Thermometer indicates a conducive deal environment for M&A activity in the life sciences sector. — Slight increase in deal appetite coupled with lower levels of debt shape the current deal environment.

DEAL APPETITE (Forward P/E ratio)

HOT

DEAL CAPACITY (Net Debt/EBITDA)

MODERATE 21.5

30 Sep 2021 30 Sep 2022

Note: Source:

0.8x

21.8 (b)

COOL

0.4x

30 Sep 2021 30 Sep 2022

(c)

(a) Refers to 90% quantile at respective quarter-end (b) Forward P/E ratio: net profit expected for 2022 to market cap in 2021 (c) Deal capacity: expected net debt to EBITDA in 2022 Thomson One, Capital IQ, KPMG Germany Analysis

© 2021 KPMG AG Wirtschaftsprüfungsgesellschaft, a corporation under German law and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

1


Turn static files into dynamic content formats.

Create a flipbook